Charles River Laboratories (CRL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Charles River Laboratories (CRL) has a cash flow conversion efficiency ratio of 0.063x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($179.72 Million) by net assets ($2.85 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Charles River Laboratories for the company's overall valuation and market capitalisation.
Charles River Laboratories - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Charles River Laboratories's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Charles River Laboratories Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Charles River Laboratories ranked by their cash flow conversion efficiency. Explore Charles River Laboratories earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Elia Group SA/NV
BR:ELI
|
0.095x |
|
YTL Power International Bhd
KLSE:6742
|
0.069x |
|
SPIC Dongfang New Energy Corp
SHE:000958
|
-0.007x |
|
Jindal Steel & Power Limited
NSE:JINDALSTEL
|
0.065x |
|
Great Wall Motor Co Ltd
SHG:601633
|
0.215x |
|
COLOPLAST SP.ADR 1/10 DK1
F:CBH
|
0.162x |
|
LPP S.A.
WAR:LPP
|
0.432x |
|
Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk
F:PTI
|
0.092x |
Annual Cash Flow Conversion Efficiency for Charles River Laboratories (1998–2025)
The table below shows the annual cash flow conversion efficiency of Charles River Laboratories from 1998 to 2025. View CRL share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.21 Billion | $737.65 Million | 0.230x | +9.70% |
| 2024-12-31 | $3.51 Billion | $734.58 Million | 0.209x | +12.03% |
| 2023-12-31 | $3.66 Billion | $683.90 Million | 0.187x | -8.80% |
| 2022-12-31 | $3.02 Billion | $619.64 Million | 0.205x | -30.18% |
| 2021-12-31 | $2.59 Billion | $760.80 Million | 0.294x | +15.12% |
| 2020-12-31 | $2.14 Billion | $546.58 Million | 0.255x | -11.65% |
| 2019-12-31 | $1.67 Billion | $480.94 Million | 0.289x | -12.45% |
| 2018-12-31 | $1.34 Billion | $441.14 Million | 0.330x | +10.90% |
| 2017-12-31 | $1.06 Billion | $316.26 Million | 0.297x | -14.93% |
| 2016-12-31 | $853.78 Million | $298.32 Million | 0.349x | -6.59% |
| 2015-12-31 | $765.56 Million | $286.36 Million | 0.374x | +4.94% |
| 2014-12-31 | $704.35 Million | $251.05 Million | 0.356x | +14.37% |
| 2013-12-31 | $664.66 Million | $207.14 Million | 0.312x | -9.58% |
| 2012-12-31 | $603.20 Million | $207.90 Million | 0.345x | -11.16% |
| 2011-12-31 | $529.14 Million | $205.28 Million | 0.388x | +58.09% |
| 2010-12-31 | $688.73 Million | $169.01 Million | 0.245x | +49.81% |
| 2009-12-31 | $1.37 Billion | $225.04 Million | 0.164x | -29.82% |
| 2008-12-31 | $1.20 Billion | $279.95 Million | 0.233x | +53.05% |
| 2007-12-31 | $1.86 Billion | $284.25 Million | 0.152x | +48.85% |
| 2006-12-31 | $1.60 Billion | $164.37 Million | 0.102x | -20.50% |
| 2005-12-31 | $1.84 Billion | $236.70 Million | 0.129x | +3.35% |
| 2004-12-31 | $1.48 Billion | $184.83 Million | 0.125x | -52.17% |
| 2003-12-31 | $474.80 Million | $123.77 Million | 0.261x | -26.68% |
| 2002-12-31 | $375.94 Million | $133.66 Million | 0.356x | +50.84% |
| 2001-12-31 | $302.50 Million | $71.30 Million | 0.236x | -9.08% |
| 2000-12-31 | $130.26 Million | $33.77 Million | 0.259x | +175.79% |
| 1999-12-31 | $-109.84 Million | $37.57 Million | -0.342x | -254.24% |
| 1998-12-31 | $168.56 Million | $37.38 Million | 0.222x | -- |
About Charles River Laboratories
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in … Read more